Lenalidomide Newbury

Lenalidomide, the active ingredient in Lenalidomide Newbury, is an immunomodulatory drug presented as an oral formulation for oral use. It modulates the immune response and inhibits angiogenesis, and is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing for qualified healthcare providers. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies that affect plasma cells and myeloid lineage. - Multiple myeloma: Reduces disease progression and improves survival in adult patients. - Myelodysplastic syndromes with del(5q): Improves blood counts and reduces transfusion dependence. - Mantle cell lymphoma: Contributes to disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: Persistent tiredness affecting daily activities. - Diarrhea: Loose stools that may lead to dehydration. - Nausea: Stomach upset often occurring after dosing. - Rash: Skin irritation or redness. - Constipation: Difficulty passing stool. - Peripheral neuropathy: Tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: Blood clots such as deep vein thrombosis or pulmonary embolism. - Severe neutropenia: Markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: Elevated liver enzymes or liver injury. - Secondary malignancies: Development of new cancers unrelated to original disease.

Before initiating Lenalidomide therapy, several precautions should be observed to minimize risks. - Pregnancy avoidance: Contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolism prophylaxis: Assess risk and consider anticoagulation in high‑risk patients. - Renal function monitoring: Adjust therapy based on creatinine clearance. - Hematologic monitoring: Regular CBC to detect neutropenia or anemia. - Infection vigilance: Monitor for signs of infection and manage promptly. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: May reduce lenalidomide exposure; avoid concurrent use. - Anticoagulants (warfarin, DOACs): Increased bleeding risk; avoid combination.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: May increase plasma levels; monitor for toxicity. - Immunosuppressants (e.g., cyclosporine): Potential additive immunosuppression. - Live vaccines: Reduced efficacy; avoid administration during therapy. - NSAIDs: May exacerbate thrombocytopenia; use with caution.